| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Integrated stable isotope labeling by amino acids in cell culture (SILAC) and isobaric tags for relative and absolute quantitation (iTRAQ) quantitative proteomic analysis identifies galectin-1 as a potential biomarker for predicting sorafenib resistance in liver cancer
|
Ho W.-C.; Tsai M.-H.; Feng W.-C.; Chow L.-P.; Hsu C.-H.; YU-YUN SHAO; Yeh C.-C.;Hsu C.-H.;Yu-Yun Shao;Ho W.-C.;Tsai M.-H.;Feng W.-C.;Chow L.-P.; Yeh C.-C. |
| 臺大學術典藏 |
2020-04-10T12:16:03Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Chan S.-Y.; Shau W.-Y.; YU-YUN SHAO; Yu-Yun Shao;Shau W.-Y.;Chan S.-Y.;Lu L.-C.;Hsu C.-H.;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
|
Yu-Yun Shao;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib
|
Lin T.-H.;Yu-Yun Shao;Chan S.-Y.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; Lin T.-H.; YU-YUN SHAO; Chan S.-Y.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:02Z |
Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan
|
Yeh Y.-C.; Lai C.-L.; Lin Z.-Z.; Cheng A.-L.; Lai M.-S.; Yu-Yun Shao;Hsu C.-H.;Yeh K.-H.;Chen H.-M.;Yeh Y.-C.;Lai C.-L.;Lin Z.-Z.;Cheng A.-L.;Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Yeh K.-H.; Chen H.-M. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Modified CLIP with objective liver reserve assessment retains prognosis prediction for patients with advanced hepatocellular carcinoma
|
YU-YUN SHAO; Liu T.-H.; Lee Y.-H.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:01Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Fu W.-M.; Chen H.-M.; Lee Y.-H.; Lai M.-S.; YU-YUN SHAO; Hsu C.-H.; Lin C.-P.; Lin C.-P.;Hsu C.-H.;Fu W.-M.;Chen H.-M.;Lee Y.-H.;Lai M.-S.;Yu-Yun Shao |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma
|
Lin H.-H.; Feng W.-C.; Lu L.-C.; YU-YUN SHAO; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Prescription patterns of sorafenib and outcomes of patients with advanced hepatocellular carcinoma: A national population study
|
Yeh Y.-C.; Chen P.-J.; Lu L.-C.;Chen P.-J.;Yeh Y.-C.;Hsu C.-H.;Chen H.-M.;Lai M.-S.;Yu-Yun Shao;Cheng A.-L.; Lu L.-C.; Hsu C.-H.; Chen H.-M.; Lai M.-S.; YU-YUN SHAO; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:59Z |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)
|
Chen Y.-C.; Ohishi N.; O’Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Frenette C.; Lin Z.-Z.; YU-YUN SHAO; Wan P.; Ma J.; Lyashchenko S.K.; Gansukh B.; Pandit-Taskar N.; Ruan S.; Beylergil V.; O’Donoghue J.; Abou-Alfa G.K.;Yen C.-J.;Hsu C.-H.;O’Donoghue J.;Beylergil V.;Ruan S.;Pandit-Taskar N.;Gansukh B.;Lyashchenko S.K.;Ma J.;Wan P.;Yu-Yun Shao;Lin Z.-Z.;Frenette C.;O’Neil B.;Schwartz L.;Smith-Jones P.M.;Ohtomo T.;Tanaka T.;Morikawa H.;Maki Y.;Ohishi N.;Chen Y.-C.;Agajanov T.;Boisserie F.;Di Laurenzio L.;Lee R.;Larson S.M.;Cheng A.-L.;Carrasquilo J.A.; Abou-Alfa G.K.; Yen C.-J.; Hsu C.-H.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; Cheng A.-L.; Carrasquilo J.A. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Right or left? Side selection for a totally implantable vascular access device: A randomised observational study
|
Lin W.-Y.;Lin C.-P.;Hsu C.-H.;Lee Y.-H.;Lin Y.-T.;Hsu M.-C.;Yu-Yun Shao; Lin W.-Y.; Lin C.-P.; Hsu C.-H.; Lee Y.-H.; Lin Y.-T.; Hsu M.-C.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Successful Hepatic Arterial Infusion of Chemotherapy in a Patient with Advanced Hepatocellular Carcinoma and Impending Liver Failure
|
Liu T.-H.;Hsu C.-H.;Yu-Yun Shao; Liu T.-H.; Hsu C.-H.; YU-YUN SHAO |
| 臺大學術典藏 |
2020-04-10T12:15:57Z |
Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells
|
Yu-Yun Shao;Hsieh M.-S.;Wang H.-Y.;Li Y.-S.;Lin H.;Hsu H.-W.;Huang C.-Y.;Hsu C.-H.;Cheng A.-L.; YU-YUN SHAO; Hsieh M.-S.; Wang H.-Y.; Li Y.-S.; Lin H.; Hsu H.-W.; Huang C.-Y.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:56Z |
Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
|
Lu L.-C.;Lee Y.-H.;Chang C.-J.;Shun C.-T.;Fang C.-Y.;Yu-Yun Shao;Liu T.-H.;Cheng A.-L.;Hsu C.-H.; Lu L.-C.; Lee Y.-H.; Chang C.-J.; Shun C.-T.; Fang C.-Y.; YU-YUN SHAO; Liu T.-H.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:55Z |
Considerations of heterogeneity in clinical trials for hepatocellular carcinoma
|
Liu T.-H.;Yu-Yun Shao;Lu L.-C.;Shen Y.-C.;Hsu C.;Lin Z.-Z.;Hsu C.-H.;Cheng A.-L.; Liu T.-H.; YU-YUN SHAO; Lu L.-C.; Shen Y.-C.; Hsu C.; Lin Z.-Z.; Hsu C.-H.; Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
|
Shih I.-L.; Hung Y.-P.; Chang C.-J.; Shen Y.-C.; Guo J.-C.; Liu T.-H.; Hsu C.-H.; Cheng A.-L.; Yen C.-J.; Chao Y.; Lu L.-C.; Hsu C.; YU-YUN SHAO; Lu L.-C.;Hsu C.;Yu-Yun Shao;Chao Y.;Yen C.-J.;Shih I.-L.;Hung Y.-P.;Chang C.-J.;Shen Y.-C.;Guo J.-C.;Liu T.-H.;Hsu C.-H.;Cheng A.-L. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma
|
Yu-Yun Shao;Li Y.-S.;Hsu H.-W.;Lin H.;Wang H.-Y.;Wo R.R.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Li Y.-S.; Hsu H.-W.; Lin H.; Wang H.-Y.; Wo R.R.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:54Z |
Neutrophil-to-lymphocyte Ratio and Use of Antibiotics Associated With Prognosis in Esophageal Squamous Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors
|
Guo J.-C.;Lin C.-C.;Lin C.-Y.;Hsieh M.-S.;Kuo H.-Y.;Lien M.-Y.;Yu-Yun Shao;Huang T.-C.;Hsu C.-H.; Guo J.-C.; Lin C.-C.; Lin C.-Y.; Hsieh M.-S.; Kuo H.-Y.; Lien M.-Y.; YU-YUN SHAO; Huang T.-C.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-10T12:15:53Z |
Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma
|
Yu-Yun Shao;Liu T.-H.;Hsu C.;Lu L.-C.;Shen Y.-C.;Lin Z.-Z.;Cheng A.-L.;Hsu C.-H.; YU-YUN SHAO; Liu T.-H.; Hsu C.; Lu L.-C.; Shen Y.-C.; Lin Z.-Z.; Cheng A.-L.; Hsu C.-H. |
| 臺大學術典藏 |
2020-04-09T09:42:28Z |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: A meta-analysis of randomized clinical trials
|
Shao, Y.-Y.; Shau, W.-Y.; Chan, S.-Y.; Lu, L.-C.; Hsu, C.-H.; Cheng, A.-L. |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-04-09T09:31:03Z |
Key opioid prescription concerns in cancer patients: A nationwide study
|
Shao, Y. Y.; Lin, C. P.; Hsu, C. H.; Fu, W. M.; Chen, H. M.; Lee, Y. H.; Lai, M. S. |
| 臺大學術典藏 |
2020-04-08T02:10:16Z |
Drug-loaded hyaluronic acid hydrogel as a sustained-release regimen with dual effects in early intervention of tendinopathy
|
Hsiao M.-Y.;Lin A.-C.;Liao W.-H.;Tyng-Guey Wang;Hsu C.-H.;Chen W.-S.;Lin F.-H.; Hsiao M.-Y.; Lin A.-C.; Liao W.-H.; TYNG-GUEY WANG; Hsu C.-H.; Chen W.-S.; Lin F.-H. |
